Document is current
Any future updates will be listed below
-
Authors
Lehle, Sarah
Emons, Julius
Hack, Carolin C.
Heindl, Felix
Hein, Alexander
Preuß, Caroline
Seitz, Katharina
Zahn, Anna L.
Beckmann, Matthias W.
Fasching, Peter A.
Ruebner, Matthias
Huebner, Hanna
-
Funding
Funding for this research was provided by:
Friedrich-Alexander-Universität Erlangen-Nürnberg
- License Information
-
More Information
Article History
Received: 5 August 2022
Accepted: 28 December 2022
First Online: 7 January 2023
Competing interests
: JE reports personal fees from Pfizer, Eisai and Novartis, outside the submitted work. CCH has received honoraria from Roche, Pfizer and Novartis. PAF reports personal fees from Novartis, grants from Biontech, personal fees from Pfizer, personal fees from Daiichi-Sankyo, personal fees from AstraZeneca, personal fees from Eisai, personal fees from Merck Sharp & Dohme, grants from Cepheid, personal fees from Lilly, personal fees from Pierre Fabre, personal fees from Seattle Genetics, personal fees from Roche, personal fees from Hexal, during the conduct of the study. All other authors declare no conflict of interest.
